SCHEMBL7200705

SCHEMBL7200705

Cc1noc(-c2ccc(CO)cc2)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.61
LMNA P02545 2/20 0.50
THRB P10828 1/20 0.50
S1PR1 P21453 3/20 0.49
S1PR3 Q99500 2/20 0.49
NOTUM Q6P988 2/20 0.47
AOC3 Q16853 2/20 0.47
MAPT P10636 3/20 0.47
TP53 P04637 2/20 0.47
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
ALDH1A1 P00352 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
BCHE P06276 1/20 0.43
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
DRD2 P14416 1/20 0.42
PARP1 P09874 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13415305 0.84 ACHE (0.80) ACHELMNATHRBAOC3MAPT
SCHEMBL8428076 0.84 ACHE (0.62) ACHELMNATHRBS1PR1NOTUM
SCHEMBL15444665 0.82 ACHE (0.61) ACHELMNATHRBS1PR1AOC3
SCHEMBL5121524 0.82 ACHE (0.61) ACHELMNATHRBS1PR1AOC3
SCHEMBL3456530 0.81 NPC1 (0.66) LMNAS1PR1S1PR3MAPTTP53
SCHEMBL10139416 0.81 ACHE (0.59) ACHELMNATHRBS1PR1S1PR3
SCHEMBL30018059 0.80 S1PR1 (0.56) ACHES1PR1S1PR3NOTUMMAPT
SCHEMBL22469950 0.80 S1PR1 (0.56) ACHES1PR1S1PR3NOTUMMAPT
SCHEMBL400963 0.79 ACHE (0.67) ACHELMNATHRBAOC3MAPT
SCHEMBL5952049 0.79 ACHE (0.57) ACHELMNATHRBS1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268494-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS Merck Frosst Canada & Co. (CA) 2003-01-02 EP disclosed
US-6498151-B2 PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS MERCK FROSST CANADA & CO. (CA) 2002-12-24 US disclosed
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors MERCK FROSST CANADA LTD. (CA) 2002-07-11 US disclosed
WO-2001070753-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors PTPRF, PTPRS, PTPRO ACHE 4356/4885LMNA 4857/4885THRB 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.